Evidence map›Paper›PMID 36750643›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Relative Effectiveness of Coronavirus Disease 2019 Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period-United States, 1 January 2022 to 31 March 2022.

Lyudmyla Kompaniyets, Ryan E Wiegand, Adewole C Oyalowo, Lara Bull-Otterson, Heartley Egwuogu, Trevor Thompson, Ka'imi Kahihikolo, Lori Moore, Nkenge Jones-Jack, Roua El Kalach and 7 more

Erratum issuedOpen access · hybridAbstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it

0cells of the map it votes in

7citing papers in PubMed, 2 pooled it

3.3field-weighted citation impact, top 8% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

COVID-19 Vaccine Effectiveness of Booster Doses Against Delta and Omicron Variants Over Follow-up Times Using Longitudinal Meta-analysis.Journal of research in health sciences · 2024
Pooled it
New variants of COVID-19 (XBB.1.5 and XBB.1.16, the "Arcturus"): A review of highly questioned concerns, a brief comparison between different peaks in the COVID-19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at-risk groups.Immunity, inflammation and disease · 2024
Pooled it
Privacy preserving record linkage for public health action: opportunities and challenges.Journal of the American Medical Informatics Association : JAMIA · 2024
Article
Methodology of comparative studies on the relative effectiveness of COVID-19 vaccines: a systematic review.Osong public health and research perspectives · 2024
Article
Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States.Vaccine: X · 2024
Article
Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.Vaccine · 2023
Article
Modernizing Public Health Data Systems and Workforce Capacity: The Centers for Disease Control and Prevention's Public Health Informatics Fellowship Program.Journal of public health management and practice : JPHMP
Article

4 · The record

Corrections and comments

Erratum issued
Correction to: Relative Effectiveness of Coronavirus Disease 2019 Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period-United States, 1 January 2022 to 31 March 2022.2023

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Lyudmyla KompaniyetsCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Ryan E WiegandCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Adewole C OyalowoCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Lara Bull-OttersonCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Heartley EgwuoguCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Trevor ThompsonCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Ka'imi KahihikoloCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Lori MooreCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Nkenge Jones-JackCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Roua El KalachCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Arunkumar SrinivasanCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Ashley MesserCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Tamara PilishviliNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Aaron M HarrisCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Adi V GundlapalliCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Ruth Link-GellesCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-9617-806X

Tegan K BoehmerCOVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Centers for Disease Control and Prevention · US

Funding

Intramural CDC HHS CC999999

6 · The paper itself

Abstract

backgroundSmall sample sizes have limited prior studies' ability to capture severe COVID-19 outcomes, especially among Ad26.COV2.S vaccine recipients. This study of 18.9 million adults aged ≥18 years assessed relative vaccine effectiveness (rVE) in three recipient cohorts: (1) primary Ad26.COV2.S vaccine and Ad26.COV2.S booster (2 Ad26.COV2.S), (2) primary Ad26.COV2.S vaccine and mRNA booster (Ad26.COV2.S+mRNA), (3) two doses of primary mRNA vaccine and mRNA booster (3 mRNA).

methodsWe analyzed two de-identified datasets linked using privacy-preserving record linkage (PPRL): insurance claims and retail pharmacy COVID-19 vaccination data. We assessed the presence of COVID-19 diagnosis during January 1-March 31, 2022 in: (1) any claim, (2) outpatient claim, (3) emergency department (ED) claim, (4) inpatient claim, and (5) inpatient claim with intensive care unit (ICU) admission. rVE for each outcome comparing three recipient cohorts (reference: two Ad26.COV2.S doses) was estimated from adjusted Cox proportional hazards models.

resultsCompared with two Ad26.COV2.S doses, Ad26.COV2.S+mRNA and three mRNA doses were more effective against all COVID-19 outcomes, including 57% (95% CI: 52-62) and 62% (95% CI: 58-65) rVE against an ED visit; 44% (95% CI: 34-52) and 54% (95% CI: 48-59) rVE against hospitalization; and 48% (95% CI: 22-66) and 66% (95% CI: 53-75) rVE against ICU admission, respectively.

conclusionsThis study demonstrated that Ad26.COV2.S + mRNA doses were as good as three doses of mRNA, and better than two doses of Ad26.COV2.S. Vaccination continues to be an important preventive measure for reducing the public health impact of COVID-19.

Indexed as

COVID-19SARS-CoV-2Ad26COVS1AdolescentAdultCOVID-19 TestingCOVID-19 VaccinesHumansRNA, MessengerVaccinationAd26COVS1COVID-19 VaccinesRNA, Messengerbooster doseCOVID-19J&JSARS-CoV-2 vaccine effectiveness

Identifiers

PMID36750643

DOI10.1093/cid/ciad063

PMCPMC11179631

OpenAlexW4319461286

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.